Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Merck's Medicaid vaccine demonstration project

Executive Summary

Virginia Medicaid has applied for a federal Medicaid waiver to allow it to participate in Merck's vaccine pilot project ("The Pink Sheet" April 13, T&G-3). The waiver would allow the state's Medicaid agency to pay Merck directly for the vaccines, which the company would supply to physician offices. If the waiver is approved, Merck is expected to begin shipments in December, initially focusing on the firm's measles, mumps, rubella vaccine MMRII. Arizona, California, Arkansas and New Jersey have also expressed interest in the pilot project. Payments are based on the discounted price Merck provides to the Centers for Disease Control's vaccines program, plus a fee for distribution. House and Senate legislators reportedly have discussed a change in federal Medicaid statutes to permit states to participate in such a program without going through the waiver process; the issue could come up when Congress reconvenes next year.

You may also be interested in...

Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data

Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011

FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance

FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials

Shire Hopes To Sow Future Deals With $50M Venture Fund

Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts